SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy

Overview of attention for article published in Frontiers in immunology, December 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 41 news outlets

twitter: 6 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 6 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 1 citation of this research output.

1

The most recent citing publication is shown below. View this citation on Dimensions.

A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers

Article in Frontiers in Immunology (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.